Clinical Trials on Thrombocytopenia in United States

Total 348 results

GlaxoSmithKline

Completed

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

Purpura, Thrombocytopaenic, Idiopathic

United States
Amgen

Completed

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura

United States, Canada, Australia
Veralox Therapeutics

Recruiting

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

Heparin Induced Thrombocytopenia | Thrombocytopenia, Immune

United States
GlaxoSmithKline

Withdrawn

Milk-only Lactation Study for Patients on Eltrombopag

Thrombocytopaenia

United States
GlaxoSmithKline

Completed

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) (PETIT)

Purpura, Thrombocytopaenic, Idiopathic

United States, France, Netherlands, Spain, United Kingdom, Canada
GlaxoSmithKline

Completed

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

Thrombocytopaenia

United States
Eisai Inc.

Completed

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

Idiopathic Thrombocytopenia Purpura

United States
GlaxoSmithKline

Completed

Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom
Weill Medical College of Cornell University

Terminated

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone (Dex/Rituxan)

Idiopathic Thrombocytopenia Purpura

United States
Bloodworks
University of Washington

Completed

A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura (NACinTTP)

Purpura, Thrombotic Thrombocytopenic | TTP

United States
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
Weill Medical College of Cornell University
Children's Hospital of Orange County

Completed

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

Immune Thrombocytopenia

United States
Octapharma

Active, not recruiting

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Chronic Immune Thrombocytopenia

United States
Weill Medical College of Cornell University
GlaxoSmithKline

Completed

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenia

United States
Weill Medical College of Cornell University
Novartis

Terminated

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

Immune Thrombocytopenia

United States
National Institutes of Health Clinical Center (CC)

Completed

Daclizumab to Treat Chronic Immune Thrombocytopenia

Thrombocytopenia

United States
GlaxoSmithKline

Completed

LENS - Long-term Eltrombopag Observational Study (LENS)

Purpura, Thrombocytopaenic, Idiopathic

United States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura

United States
GlaxoSmithKline

Completed

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States
Bioverativ, a Sanofi company

Completed

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP)

Germany, United States, Czechia, Netherlands, Spain, United Kingdom
UCB Biopharma SRL

Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy2)

Primary Immune Thrombocytopenia

United States, Bulgaria, China, France, Germany, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
Stanford University
Weill Medical College of Cornell University

Completed

Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics

Immune Thrombocytopenia

United States
Amgen

Completed

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Idiopathic Thrombocytopenic Purpura

Italy, United States, Germany, Czechia, United Kingdom, Australia, Spain, Poland, France
Ohio State University
Food and Drug Administration (FDA)

Completed

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura

United States
Hematology and Oncology Specialists

Unknown

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Autoimmune Thrombocytopenic Purpura

United States
Baylor College of Medicine

Active, not recruiting

Post IVIG Medication in Children With Immune Thrombocytopenia

Immune Thrombocytopenia

United States
Novartis Pharmaceuticals

Completed

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom, Hong Kong, United States, Germany, Italy, Netherlands, Spain, Taiwan, Thailand, Canada, Denmark, Pakistan, Romania, Slovenia, Russian Federation, Slovakia, Sweden, Poland, China, New Zealand, Ukraine, Australia, Austria and more
Octapharma

Terminated

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
Principia Biopharma, a Sanofi Company

Active, not recruiting

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Immune Thrombocytopenic Purpura

United States, Australia, Bulgaria, Canada, Czechia, Netherlands, Norway, United Kingdom
Pfizer

Recruiting

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

United States, Australia, Canada, Czechia, Poland, Hungary, United Kingdom
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

Thrombocytopaenia

Spain, Taiwan, Bulgaria, United States, Argentina, Russian Federation, Germany, Korea, Republic of, Austria, India, Italy, United Kingdom, Poland, Romania, Ukraine, Hungary, Peru, Czech Republic, Mexico
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Idiopathic Thrombocytopenic Purpura (ITP)

United States
Bioverativ, a Sanofi company

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

Purpura, Thrombocytopenic, Idiopathic

United Kingdom, United States, Germany
Weill Medical College of Cornell University
Novartis

Completed

Safety and Efficacy of Eltrombopag at Escalated Doses

Immune Thrombocytopenia | Platelet Disorder

United States
Icahn School of Medicine at Mount Sinai
Beth Israel Medical Center

Terminated

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (TTP)

Thrombotic Thrombocytopenic Purpura

United States
Novartis Pharmaceuticals

Recruiting

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Primary Immune Thrombocytopenia (ITP)

Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, Argentina, Australia, United Kingdom, Poland, United States
GlaxoSmithKline

Completed

Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

Thrombocytopaenia

United States
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Thailand, Korea, Republic of, United Kingdom, New Zealand, Germany, Greece, Hong Kong, Pakistan, Poland, Romania, Russian Federation, Slovenia, Taiwan
Shionogi

Terminated

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP)

United States
Eisai Inc.

Terminated

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Idiopathic Thrombocytopenic Purpura

United States
Neufeld, Ellis J, MD, PhD
Terrana ITP Research Fund

Completed

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura

United States
Weill Medical College of Cornell University
Genentech, Inc.; Biogen

Completed

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Immune Thrombocytopenic Purpura

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

Purpura, Thrombocytopenic, Idiopathic | Immune Thrombocytopenic Purpura

United States
Eisai Inc.

Completed

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

Idiopathic Thrombocytopenic Purpura (ITP)

United States
Novartis Pharmaceuticals

Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

Primary Immune Thrombocytopenia (ITP)

China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
Octapharma

Terminated

Octaplas Adult TTP Trial

Thrombotic Thrombocytopenic Purpura

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Thrombocytopaenia

United States, Germany, Israel, Belgium, Finland, Ireland, Italy, Greece, India, Czech Republic, Hungary, Canada, Poland
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

Nonneoplastic Condition

United States

Clinical Trials on Thrombocytopenia in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations